Danish Pharma Stock News

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...

Earlier this week, Novo Nordisk announced that the European Medicines Agency approved an updated Rybelsus label to reflect cardiovascular benefits in type 2 diabetes, following the results of the SOUL trial presented at the European Association for the Study of Diabetes 2025 Congress in Vienna. This approval positions Rybelsus as the first oral GLP-1 therapy in the EU with proven cardiovascular benefit, potentially expanding its clinical reach among patients with type 2 diabetes at increased...

Vestas Wind Systems (CPSE:VWS) just turned heads with its new deal in Germany. The company has locked in an order to deliver and service 12 of its flagship V172-7.2 MW wind turbines, a project totaling 86 MW for WestfalenWIND. What stands out is not just the size of the turbines, but also the depth of the partnership, with a 20-year service agreement attached. For investors weighing their next move, this is the kind of business expansion that prompts a closer look at where Vestas might be...

Earlier this month, HBM Healthcare Investments announced that its portfolio company Swixx BioPharma signed a multi-regional distribution and services agreement with H. Lundbeck A/S, covering Lundbeck's central nervous system portfolio in South-East Europe, Turkey, and Latin America, as part of a wider transition by Lundbeck to a partnership-based commercial operating model in 27 international markets with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals. This shift reflects a...

Earlier this month, a leading Indian steelmaker announced it has chosen FLSmidth to deliver core mining technologies for one of the world's most efficient and sustainable iron ore beneficiation plants, marking the fourth consecutive contract between the companies in nine months. This order features the world's largest filtered tailings system and high-rate thickeners, underlining FLSmidth's role in advancing sustainability and water conservation in mining operations. We'll examine how...

Ørsted A/S recently announced a follow-on equity offering, filing to raise DKK 59.99 billion by issuing 900,816,600 new ordinary shares at DKK 66.6 each. This sizable capital raise through a rights offering structure represents one of the largest share issuances in the company's history and signals a significant move to strengthen its financial position. Next, we'll explore how this capital-raising effort through a large-scale rights offering could impact Ørsted's investment...

Key Insights Netcompany Group's estimated fair value is kr.396 based on 2 Stage Free Cash Flow to Equity Current share...

Roblon ( CPH:RBLN B ) Third Quarter 2025 Results Key Financial Results Revenue: kr.69.4m (down 27% from 3Q 2024). Net...

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

Rovsing ( CPH:ROV ) Full Year 2025 Results Key Financial Results Revenue: kr.37.0m (down 5.7% from FY 2024). Net loss...

ChemoMetec A/S ( CPH:CHEMM ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

The Movinn A/S ( CPH:MOVINN ) share price has fared very poorly over the last month, falling by a substantial 40%. For...

Demant A/S ( CPH:DEMANT ), is not the largest company out there, but it saw significant share price movement during...

As European markets experienced a positive week, with the pan-European STOXX Europe 600 Index rising by 1.03% amid expectations of potential U.S. interest rate cuts, investors are increasingly focused on identifying value opportunities in this environment. In such conditions, stocks trading below their estimated intrinsic worth can present appealing prospects for those looking to capitalize on market inefficiencies and potential future growth.

It's been a pretty great week for ChemoMetec A/S ( CPH:CHEMM ) shareholders, with its shares surging 12% to kr.610 in...

If you have been wondering what to do with H. Lundbeck stock, you are not alone. Investors have witnessed some interesting moves lately, with shares climbing 3.3% in the last week and jumping nearly 10% over the past month. While the year-to-date return sits at a modest 1.9%, it is hard to ignore that the stock has soared more than 72% over the past three years. Despite a slight dip over the past year, the longer-term trend speaks to resilience and renewed optimism, especially as broader...

Deciding what to do with NKT stock right now might feel a bit like standing at a crossroads. Maybe you’re eyeing those recent price gains and wondering if there’s still more upside ahead, or perhaps you’re cautious after such a strong run. Over the past week, NKT shares have ticked up by 1.6%, and looking a bit further back, the 30-day return sits at an impressive 5.3%. Year-to-date, the stock has soared by 20.5%. If you zoom out even more, the long-term story gets even more interesting, with...

If you have been watching Zealand Pharma (CPSE:ZEAL), you are likely wondering what to make of the recent movement in its stock price. There is not an obvious catalyst behind the recent swing, but sometimes these smaller moves, especially when lacking a clear driver, can pique investor curiosity. Is this just noise, or is the market quietly repricing Zealand Pharma in anticipation of what comes next? Looking at the bigger picture, Zealand Pharma stock has had a tough year, with shares sliding...

Thinking about what to do with your Københavns Lufthavne shares, or considering a move into this Danish airport operator? You’re not alone. The stock has generated plenty of buzz lately, with the price rising a staggering 64.4% over the past year. Investors have clearly taken notice, especially as broader travel demand recovers and market watchers see airports as potential long-term growth engines. But it’s not just the annual returns that are catching eyes. Year-to-date, the stock is up...

Thinking about what to do with Alm. Brand stock? If you are eyeing recent share price movements, you are not alone. With Alm. Brand posting a 2.3% gain over the last week and rising 2.8% in the past month, it is clear that the stock is catching attention. But it is the bigger picture that really pops: a 31.7% year-to-date surge and an impressive 55.4% jump over the last year speak to renewed confidence among investors. Over the past three years, Alm. Brand has nearly doubled in value,...

Thinking about what to do with ISS stock? You are not alone. With so much noise in the market, deciding when to buy, hold, or move on can feel daunting. But here is the thing: ISS has shown some remarkably strong moves over the short and long term that are hard to ignore for any investor looking for growth or value. Just over the past week, the stock climbed 7.9%, and it is up 4.9% in the last month. If you widen the lens, those numbers get even more compelling, with a 52.1% surge...

Trying to decide what to do with Ringkjøbing Landbobank stock? You are not alone. After years of steady outperformance, this Danish bank keeps showing up in conversations among investors looking for both growth and stability. Its stock has climbed an impressive 209.5% over the last five years, and even after a very strong year, it is still up 17.6% so far in 2024. While there has been a brief pause lately, with a -1.0% return in the past week and -5.3% over the last month, the long-term...

Deciding what to do with Rockwool stock? You are definitely not alone—it is one of those companies that always sparks debate among investors, especially after a stretch of ups and downs that has put everyone on alert. If you have been watching the chart, you know things have been anything but boring. After a relatively flat week, the share price has taken a 15.3% drop over the past month and sits down 5.1% for the year. Over the past year, Rockwool is off 14.6%, but zoom out to three years...

ChemoMetec A/S recently announced improved full-year financial results for 2024/25, a proposed DKK 7.0 per share dividend totaling DKK 121.8 million, and issued earnings guidance projecting revenue growth for the 2025/26 financial year. This combination of higher earnings, a larger dividend, and an optimistic outlook highlights ChemoMetec's ongoing focus on both business expansion and shareholder returns. We'll consider how ChemoMetec's increased dividend proposal adds depth to its...